Therapeutic options directed against platelet activating factor, eicosanoids and bradykinin in sepsis
Therapeutic options directed against platelet activating factor, eicosanoids and bradykinin in sepsis
复制标题
DOI：
10.1093/jac/41.suppl_1.81
复制
发表时间：
1998-01-01
影响因子：
5.2
通讯作者：
Fink, MP
中科院分区：
文献类型：
--
作者：
Fink, MP
各种类花生酸、血小板活化因子（PAF）和缓激肽参与了脓毒症和脓毒性休克的发病机制。这些化合物作为脓毒症弥漫性炎症状态特征性介质的确切作用仍有待确定，但是，在动物模型中，由于用类花生酸生物合成的各种抑制剂或PAF或缓激肽受体的拮抗剂治疗，已经观察到有益效果。然而，到目前为止，还不可能将动物模型的这些令人鼓舞的结果转化为临床环境中令人信服的积极结果。
Various autacoids, including the eicosanoids, platelet activating factor (PAF) and bradykinin, have been implicated in the pathogenesis of sepsis and septic shock. The precise role of these compounds as mediators of the diffuse inflammatory state characteristic of sepsis remains to be determined, but, in animal models, beneficial effects have been observed as a result of treatment with various inhibitors of eicosanoid biosynthesis or antagonists of PAF or bradykinin receptors. To date, however, it has been impossible to translate these encouraging results from animal models into convincingly positive results in the clinical setting.